GMP Warnings Follow Thin Corrective Action Evidence, Reliance On Contract Manufacturers

摘要

FDA warning letters to VitaPurity and Morhaim Pharmalab remind the supplement firms they can’t rely on contract manufacturers and suppliers to meet FDA’s GMP practices, and that statements of corrective actions without proof are inadequate.